Osteoporosis currently affects 3.8 million people in the UK, particularly older post-menopausal women.
Theramex’s Eladinos (abaloparatide) is recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of postmenopausal bone disease.
More than 14,000 people in the UK are seeking treatment for osteoporosis after menopause and these patients (who are at very high risk of fracture) would benefit from the drug if it becomes available on the NHS in England within the next three months.
Osteoporosis is a bone disease which affects 3.8 million people in the UK. It is caused by a loss of bone density and mass, or changes to bone quality and structure, reducing bone strength and increasing the risk of fracture.
This disease occurs especially in older women after menopause because it reduces the hormone estrogen, which is important in maintaining bone density and strength, causing bone mineral density to decrease and bone fractures to become more likely.
NICE’s decision was based on the debilitating impact that osteoporosis has on patients’ daily lives and the impact it has on their mental and physical health.
This drug therapy offers an alternative for patients who do not respond to or cannot tolerate standard treatments, and it also increases bone density by stimulating the cells that make new bone, reducing the risk of fractures.
The treatment – a prefilled pen injected through the skin into the muscle – has been proven clinically effective and cost-effective.
